Evaluation of Oligonucleotide Arrays for Sequencing of the p53 Gene in DNA from Formalin-Fixed, Paraffin-Embedded Breast Cancer Specimens

Clinical Chemistry

Volumn 50, Issue 3, 2004, Pages 500-508

  Cooper, Melissa ^a   Li, Shu Qiu ^a   Bhardwaj, Tajinder ^a   Rohan, Thomas ^b   Kandel, Rita A ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; FORMALDEHYDE; PARAFFIN; PROTEIN P53;

ARTICLE; BREAST CARCINOMA; CANCER CYTODIAGNOSIS; CONTROLLED STUDY; DNA EXTRACTION; DNA MICROARRAY; DNA POLYMORPHISM; DNA SEQUENCE; EXON; GENE IDENTIFICATION; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; TISSUE FIXATION; TISSUE SECTION;

BREAST NEOPLASMS; DNA, NEOPLASM; FEMALE; FIXATIVES; FORMALDEHYDE; HUMANS; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PARAFFIN; POLYMORPHISM, GENETIC; TISSUE EMBEDDING; TUMOR SUPPRESSOR PROTEIN P53;

EID: 1542299064     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2003.025221     Document Type: Article

References (48)

1. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
2. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr, Butel JS, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature 1992; 356:215-21.
3. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT, et al. Tumor spectrum analysis in p53-mutant mice. Curr Biol 1994;4:1-7.
4. Wu X, Pandolfi PP. Mouse models for multistep tumorigenesis. Trends Cell Biol 2001;11:S2-9.
5. Rubinstein WS, O'Neill SM, Peters JA, Rittmeyer LJ, Stadler MP. Mathematically modeling for breast cancer risk assessment. Oncology 2002;16:1082-94.
6. Hussain SP, Hofseth LJ, Harris CC. Tumor suppressor genes: at the crossroads of molecular carcinogenesis, molecular epidemiology and human risk assessment. Lung Cancer 2001;2:S7-15.
7. Gasco M, Shami S, Crook T. The p53 pathway in breast cancer. Breast Cancer Res 2002;4:70-6.
8. Hartmann A, Blaszyk H, Kovach JS, Sommer SS. The molecular epidemiology of p53 gene mutations in human breast cancer. Trends Genet 1997;13:27-33.
9. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985;312:146-51.
10. Sakorafas GH, Drespis E, Pavlakis G. Risk estimation for breast cancer development; a clinical perspective. Surg Oncol 2002;10: 183-92.
11. Schmitt FC, Leal CV, Lopes C. p53 protein expression and nuclear DNA content in breast intraductal proliferations. J Pathol 1995; 1176:233-41.
12. Younes M, Lebovitz RM, Bommer KE, Cagle PT, Morton D, Khan S, et al. p53 accumulation in benign breast biopsy specimens. Hum Pathol 1995;26:155-8.
13. Alexiev BA, Bassarova AV, Popovska SL, Popov AA, Christov CZ. Expression of c-erbB-2 oncogene and p53 tumor suppressor gene in benign and malignant breast tissue: correlation with proliferative activity and prognostic index. Gen Diagn Pathol 1997;142: 271-9.
14. Kalogeraki A, Panayiotides J, Tamiolakis D, Tzarrdi M, Chaniotis V, Chalkiadakis G, et al. P53 expression in patients with malignant and benign breast diseases. Anticancer Res 2000;20:1801-5.
15. Gudlaugsdottir S, Sigurdardottir V, Snorradottir M, Jonasson JG, Ogmundsdottir H, Eyfjord JE. P53 mutation analysis in benign and malignant breast lesions: using needle rinses from fine-needle aspirations. Diagn Cytopathol 2000;22:268-74.
16. Kandel R, Li SQ, Ozcelik H, Rohan T. p53 protein accumulation and mutations in normal and benign breast tissue. Int J Cancer 2000;87:73-8.
17. Kleer CG, Giordano TJ, Braun T, Oberman HA. Pathologic, immunohistochemical, and molecular features of benign and malignant phylloides tumors of the breast. Mod Pathol 2001;14:185-90.
18. Rohan TE, Hartwick W, Miller AB, Kandel RA. Immunohistochemical detection of c-erbB-2 and p53 in benign breast disease and breast cancer risk. J Natl Cancer Inst 1998;90:1262-9.
19. Millikan R, Hulka B, Thor A, Zhang Y, Edgerton S, Zhang X, et al. P53 mutations in benign breast tissue. J Clin Oncol 1995;13: 2293-300.
20. Davidoff AM, Kerns BJ, Iglehart JD, Marks JR. Maintenance of p53 alterations throughout breast cancer progression. Cancer Res 1991;51:2605-10.
21. Jackson DP, Lewis FA, Taylor GR, Boylston AW, Quirke P. Tissue extraction of DNA and RNA and analysis by the polymerase chain reaction. J Clin Pathol 1990;43:499-504.
22. Serth J, Kuczyk MA, Paeslack U, Lichtinghagen R, Jonas U. Quantitation of DNA extracted after micropreparation of cells from frozen and formalin-fixed tissue sections. Am J Pathol 2000;156: 1189-96.
23. Mies C. Molecular biological analysis of paraffin-embedded tissues. Hum Pathol 1994;25:555-60.
24. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A 1977;74:5463-7.
25. Sjögren S, Inganäs M, Norberg T, Lindgren A, Nordgren H, Holmberg L, et al. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst 1996;88:173-82.
26. Scheffner M, Huibregtse RD, Vierstttra RD, Howley PM. The HPV-16E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993;75:495-505.
27. Tolbert DM, Noffsinger AE, Miller MA, DeVoe GW, Stemmermann GN, Macdonald JS, et al. p53 immunoreactivity and single-strand conformational polymorphism analysis often fail to predict p53 mutational status. Mod Pathol 1999;12:54-60.
28. Kutach LS, Bolshakov S, Ananthaswamy HN. Detection of mutations and polymorphisms in the p53 tumor suppressor gene by single-strand conformation polymorphism and analysis. Electrophoresis 1999;20:1204-10.
29. Pease AC, Solas D, Sullivan EJ, Cronin MT, Holmes CP, Fodor SP. Light generated oligonucleotide arrays for rapid DNA sequence analysis. Proc Natl Acad Sci U S A 1994;91:5022-6.
30. Fodor SP, Read JL, Pirrung MC, Stryer L, Lu AT, Solas D. Light-directed spatially addressable parallel chemical synthesis. Science 1991;251:767-73.
31. Wen WH, Bernstein L, Lescallett J, Beazer-Barclay Y, Sullivan-Halley J, White M, et al. Comparison of TP53 mutations identified by oligonucleotide microarray and conventional DNA sequence analysis. Cancer Res 2000;60:2716-22.
32. Ahrendt SA, Halachmi S, Chow JT, Wu L, Halachmi N, Yang SC, et al. Rapid p53 sequence analysis in primary lung cancer using an oligonucleotide probe array. Proc Natl Acad Sci U S A 1999;96: 7382-7.
33. Tönisson N, Zernant J, Kurg A, Pavel H, Slavin G, Roomere H, et al. Evaluating the arrayed primer extension resequencing assay of TP53 tumor suppressor gene. Proc Natl Acad Sci U S A 2002;99: 5503-8.
34. Rosenblum BB, Llee LG, Spurgeon SL, Khan SH, Menchen SM, Heiner CR, et al. New dye-labeled terminators for improved DNA sequencing patterns. Nucleic Acids Res 1997;15:4500-4.
35. Wikman FP, Lu M-L, Thykjaer T, Diesen SH, Andersen LD, Cordon-Cardo C, et al. Evaluation of the performance of a p53 sequencing microarray chip using 140 previously sequences bladder tumor samples. Clin Chem 2000;46:1555-61.
36. Tabor S, Richardson CC. DNA sequence analysis with a modified bacteriophage T7 DNA polymerase. Proc Natl Acad Sci USA 1987;84:4767-71.
37. Eckert KA, Kunkel TA. DNA polymerase fidelity and the polymerase chain reaction. PCR Methods Appl 1991;1:17-24.
38. Williams C, Ponten F, Moberg C, Soderkvist P, Uhlen M, Ponten J, et al. A high frequency of sequence alterations is due to formalin fixation of archival specimens. Am J Pathol 1999;155:1467-71.
39. Southern E, Mir K, Shchepinoov M. Molecular interactions on microarrays. Nat Genet 1999;21:5-9.
40. Paabo S, Irwin DM, Wilson AC. DNA damage promotes jumping between templates during enzymatic amplification. J Biol Chem 1990;265:4718-21.
41. Nadji M, Meng L, Lin L, Nassiri M, Morales AR. Detection of p53 gene abnormality by sequence analysis of archival paraffin tissue. A comparison with fresh-frozen specimens. Diagn Mol Pathol 1996;5:279-83.
42. Pollett A, Bedard YC, Li SQ, Rohan T, Kandel R. Correlation of p53 mutations in ThinPrep-processed fine needle breast aspirates with surgically resected breast cancers. Mod Pathol 2000;13: 1173-9.
43. Soong R, Iacopetta BJ. A rapid and nonisotopic method for screening and sequencing of p53 gene mutations in formalin-fixed, paraffin-embedded tumors. Mod Pathol 1997;10:252-8.
44. Blomeke B, Bennett WP, Harris CC, Shields P. Serum, plasma and paraffin-embedded tissues as sources of DNA for studying cancer susceptibility genes. Carcinogenesis 1997;18:1271-5.
45. Giercksky HE, Thorstensen L, Qvist H, Nesland JH, Lothe RA. Comparison of genetic changes in frozen biopsies and microdissected archival material from the same colorectal liver metastases. Diagn Mol Pathol 1997;6:318-25.
46. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 2002;19:607-14.
47. International Agency for Research on Cancer, www.iarc.fr (Accessed June 2003).
48. Shiao YH, Buzard GS, Weghorst CM, Rice JM. DNA template as a source of artifact in the detection of p53 gene mutations using archived tissue. Biotechniques 1997;22:608-12.